{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:12:04Z","timestamp":1687795924727},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e31826fb607","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"840-841","source":"Crossref","is-referenced-by-count":5,"title":["A Case of Valproate Toxicity Related to Isoniazid"],"prefix":"10.1097","volume":"32","author":[{"given":"Jonathan T.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan Walker","family":"Nesmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"Mattox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-23-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1157.1986.tb03534.x","article-title":"Reversible valproic acid-induced dementia: a case report.","volume":"27","author":"Zaret","year":"1986","journal-title":"Epilepsia"},{"key":"R2-23-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410140107","article-title":". Plasma concentrations of sodium valproate: their clinical value.","volume":"14","author":"Turnbull","year":"1983","journal-title":"Ann Neurol"},{"key":"R3-23-20210128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.7326\/0003-4819-120-7-199404010-00010","article-title":"Physician evaluation and management of nursing home residents.","volume":"121","author":"Ouslander","year":"1994","journal-title":"Ann Intern Med"},{"key":"R4-23-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00280078","article-title":". Interaction between isoniazid and valproate: a case of valproate overdosage.","volume":"40","author":"Jonville","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-23-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":". A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R6-23-20210128","first-page":"CD004028","article-title":". Valproate for schizophrenia.","volume":"16","author":"Schwarz","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-23-20210128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/gps.1854","article-title":". Adjunct extended-release valproate semisodium in late life schizophrenia.","volume":"23","author":"Sajatovic","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"suppl 4","key":"R8-23-20210128","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.51.5_Suppl_4.S28","article-title":"Reflections on the treatment of seizures in the elderly population.","volume":"51","author":"Rowan","year":"1998","journal-title":"Neurology"},{"key":"R9-23-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions: principles and clinical implications.","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"R10-23-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-23-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":". In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31826fb607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:48:54Z","timestamp":1687794534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31826fb607","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}